Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19022291 | T-Cell Modulatory Multimeric Polypeptides and Methods of Use Thereof | January 2025 | May 2025 | Allow | 4 | 0 | 0 | No | No |
| 18800440 | RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE | August 2024 | December 2024 | Allow | 4 | 1 | 0 | No | No |
| 18668571 | USE AND TREATMENT OF DI-AMINO ACID REPEAT-CONTAINING PROTEINS ASSOCIATED WITH ALS | May 2024 | March 2025 | Allow | 10 | 0 | 0 | No | No |
| 18665920 | Compositions and Methods for Antigen Targeting to CD180 | May 2024 | March 2025 | Allow | 10 | 1 | 0 | No | No |
| 18662554 | METHODS FOR CONTINUOUSLY INACTIVATING A VIRUS DURING MANUFACTURE OF A PROTEIN | May 2024 | April 2025 | Allow | 11 | 1 | 0 | No | No |
| 18648190 | STABILIZED INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF | April 2024 | December 2024 | Allow | 7 | 0 | 0 | No | No |
| 18616134 | RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE | March 2024 | August 2024 | Allow | 5 | 1 | 0 | No | No |
| 18612698 | SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE | March 2024 | November 2024 | Allow | 8 | 1 | 0 | No | No |
| 18612771 | MULTIVALENT EPSTEIN-BARR VIRUS-LIKE PARTICLES AND USES THEREOF | March 2024 | January 2025 | Allow | 10 | 1 | 0 | No | No |
| 18434265 | HEPATITIS B ANTIBODIES | February 2024 | January 2025 | Allow | 12 | 1 | 0 | No | No |
| 18403182 | MULTIVALENT INFLUENZA NANOPARTICLE VACCINES | January 2024 | April 2025 | Allow | 16 | 2 | 0 | Yes | No |
| 18391486 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18527937 | Immunogenic Compositions to Treat and Prevent Microbial Infections | December 2023 | May 2025 | Allow | 17 | 1 | 1 | No | No |
| 18388788 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | November 2023 | June 2024 | Allow | 7 | 0 | 0 | No | No |
| 18493004 | SUBUNIT VACCINE FOR TREATMENT OR PREVENTION OF A RESPIRATORY TRACT INFECTION | October 2023 | July 2024 | Allow | 9 | 1 | 1 | No | No |
| 18492095 | INDUCE AND ENHANCE IMMUNE RESPONSES USING RECOMBINANT REPLICON SYSTEMS | October 2023 | December 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18486459 | MHC CLASS I ASSOCIATED PEPTIDES FOR PREVENTION AND TREATMENT OF MULTIPLE FLAVI VIRUS | October 2023 | November 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18480851 | METHOD FOR ROBUST CONTROL OF GENE EXPRESSION | October 2023 | January 2025 | Allow | 15 | 1 | 0 | No | No |
| 18463235 | ROTAVIRUS VACCINES | September 2023 | February 2025 | Allow | 17 | 1 | 0 | No | No |
| 18237718 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | August 2023 | July 2024 | Allow | 10 | 1 | 0 | No | No |
| 18235464 | COMPOSITIONS INCLUDING SBI ADJUVANTS AND METHODS OF USE THEREOF | August 2023 | February 2025 | Allow | 18 | 1 | 0 | No | No |
| 18346456 | GENETICALLY ENCODED POLYPEPTIDE FOR AFFINITY CAPTURE AND PURIFICATION OF BIOLOGICS | July 2023 | August 2024 | Allow | 13 | 1 | 0 | No | No |
| 18344909 | INFLUENZA VACCINES | June 2023 | October 2024 | Allow | 16 | 1 | 0 | No | No |
| 18333591 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | June 2023 | August 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18332022 | MHC CLASS I ASSOCIATED PEPTIDES FOR PREVENTION AND TREATMENT OF MULTIPLE FLAVI VIRUS | June 2023 | August 2024 | Allow | 15 | 1 | 0 | No | No |
| 18295994 | METHODS FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ADJUNCT THERAPY | April 2023 | June 2024 | Allow | 15 | 2 | 0 | No | No |
| 18296150 | UNIVERSAL MAMMALIAN INFLUENZA VACCINE | April 2023 | April 2025 | Allow | 24 | 4 | 0 | Yes | No |
| 18185891 | METHODS AND COMPOSITIONS FOR ATTENUATING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES | March 2023 | March 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18179668 | MARBURGVIRUS CONSENSUS ANTIGENS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME | March 2023 | December 2024 | Allow | 21 | 2 | 0 | No | No |
| 18077277 | MARKER COMBINATIONS FOR DIAGNOSING INFECTIONS AND METHODS OF USE THEREOF | December 2022 | April 2025 | Allow | 28 | 3 | 0 | No | No |
| 18052541 | HENIPAVIRUS VACCINE | November 2022 | September 2024 | Allow | 22 | 1 | 0 | No | No |
| 17937719 | RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE | October 2022 | July 2024 | Allow | 21 | 1 | 0 | No | No |
| 17951674 | VIRUS AND ANTIGEN CONJUGATION | September 2022 | September 2024 | Allow | 23 | 2 | 0 | Yes | No |
| 17930065 | LASSA VIRUS VACCINE | September 2022 | June 2024 | Allow | 22 | 1 | 0 | No | No |
| 17851187 | NON-COVALENT LOADING OF PLANT PICOVIRUS PARTICLES | June 2022 | November 2024 | Allow | 28 | 3 | 0 | No | No |
| 17750612 | VACCINE COMPOSITIONS HAVING IMPROVED STABILITY AND IMMUNOGENICITY | May 2022 | August 2024 | Allow | 27 | 1 | 0 | No | No |
| 17719751 | METHOS FOR RAPID DETECTION AND IDENTIFICATION OF VIRAL NUCLEIC ACIDS | April 2022 | May 2025 | Abandon | 37 | 2 | 1 | No | No |
| 17706381 | VIRAL VACCINES AND METHODS OF FORMING THE SAME | March 2022 | June 2025 | Allow | 38 | 1 | 0 | No | No |
| 17623525 | Recombinant Herpes Zoster Vaccine Composition and Application Thereof | December 2021 | May 2025 | Allow | 40 | 1 | 0 | No | No |
| 17596306 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND DIHYDROPYRIMIDINE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | December 2021 | September 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17543206 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | December 2021 | March 2025 | Allow | 39 | 1 | 0 | No | No |
| 17596249 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND CAPSID ASSEMBLY MODULATORS BEING SULFONAMIDE DERIVATIVES | December 2021 | September 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17596162 | Designed Inhibitors of Tight Junction Formation | December 2021 | May 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17615493 | PREPARATION OF ZINC RISEDRONATE MICRO/NANO ADJUVANT AND USE THEREOF AS VACCINE ADJUVANT | November 2021 | July 2025 | Allow | 44 | 2 | 0 | No | No |
| 17613331 | NOROVIRUS-BINDING PEPTIDE | November 2021 | March 2025 | Allow | 40 | 1 | 0 | No | No |
| 17612208 | VACCINE SPRAY EQUIPMENT | November 2021 | June 2025 | Allow | 43 | 1 | 0 | No | No |
| 17528891 | MONOCLONAL ANTIBODY FOR SARS-CoV-2 SPIKE PROTEIN | November 2021 | August 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17610643 | TREATMENT METHODS | November 2021 | August 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17606811 | A SUBUNIT VACCINE FOR TREATMENT OR PREVENTION OF A RESPIRATORY TRACT INFECTION | October 2021 | July 2024 | Allow | 33 | 1 | 0 | No | No |
| 17511346 | ALL-IN-ONE KIT FOR ON-SITE MOLECULAR DIAGNOSIS AND MOLECULAR DIAGNOSIS METHOD USING SAME | October 2021 | August 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17438178 | DENGUE VIRUS VACCINE | October 2021 | February 2025 | Allow | 41 | 1 | 0 | No | No |
| 17480073 | COMPOSITIONS AND VACCINES FOR TREATING AND/OR PREVENTING VIRAL INFECTIONS, AND METHODS OF USING THE SAME | September 2021 | March 2025 | Allow | 41 | 1 | 0 | No | No |
| 17435145 | PORCINE EPIDEMIC DIARRHEA (PED) VIRUS VACCINE COMPOSITION AND PREPARATION METHOD THEREOF | August 2021 | March 2025 | Allow | 42 | 1 | 0 | No | No |
| 17424494 | Means and Methods for Improving Plant Growth and Yield | July 2021 | October 2024 | Allow | 39 | 1 | 1 | No | No |
| 17413331 | RECOMBINANT MUMPS VIRUS VACCINE EXPRESSING GENOTYPE G FUSION AND HEMAGGLUTININ-NEURAMINIDASE PROTEINS | June 2021 | May 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17413130 | INTEGRATED PROVIRAL SEQUENCING ASSAY | June 2021 | August 2024 | Allow | 39 | 1 | 0 | No | No |
| 17413026 | HEPATITIS B VIRUS VACCINE AND USES THEREOF | June 2021 | April 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17327784 | SARS-COV-2 Antigen Polypeptide, Recombinant Adeno-Associated Virus Expressing the Polypeptide, and Vaccine Containing the Virus | May 2021 | November 2024 | Allow | 42 | 1 | 1 | No | No |
| 17318719 | Stabilizing Mutants of Prefusion Sars-Cov-2 (Covid-19) Spike Protein And Improved Yeast Surface Display Engineering Platform For The Same | May 2021 | February 2025 | Allow | 45 | 4 | 1 | Yes | No |
| 17240858 | ENGINEERED CRISPR-CAS SYSTEMS AND METHODS FOR SENSITIVE AND SPECIFIC DIAGNOSTICS | April 2021 | February 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17288133 | PEPTIDES FOR INDUCING HETEROSUBTYPIC INFLUENZA T CELL RESPONSES | April 2021 | November 2024 | Allow | 43 | 1 | 0 | No | No |
| 17236516 | VIRUS DETECTION SYSTEM, VIRUS DETECTION METHOD, AND VIRUS DETECTION PROGRAM | April 2021 | December 2024 | Allow | 43 | 1 | 1 | No | No |
| 17276649 | MUCOADHESIVE LIPIDIC DELIVERY SYSTEM | March 2021 | December 2024 | Abandon | 45 | 1 | 0 | No | No |
| 17274891 | ADENOSOMES | March 2021 | June 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17268314 | GENETICALLY ENCODED POLYPEPTIDE FOR AFFINITY CAPTURE AND PURIFICATION OF BIOLOGICS | February 2021 | October 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 17264649 | T CELL RECEPTOR FOR IDENTIFYING AFP ANTIGEN | January 2021 | July 2024 | Allow | 41 | 1 | 0 | No | No |
| 17263606 | METHOD FOR ENHANCING GENE EXPRESSION USING AAV VECTOR | January 2021 | August 2024 | Allow | 43 | 1 | 0 | No | No |
| 15733861 | COMBINED PROPHYLACTIC AND THERAPEUTIC VACCINES | November 2020 | August 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 17055096 | BINDING MOIETY FOR CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES | November 2020 | April 2025 | Allow | 53 | 1 | 0 | No | No |
| 16604711 | NOVEL DELIVERY OF LARGE PAYLOADS | October 2019 | February 2025 | Allow | 60 | 2 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner BOESEN, AGNIESZKA works in Art Unit 1671 and has examined 32 patent applications in our dataset. With an allowance rate of 68.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 44 months.
Examiner BOESEN, AGNIESZKA's allowance rate of 68.8% places them in the 30% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by BOESEN, AGNIESZKA receive 1.19 office actions before reaching final disposition. This places the examiner in the 14% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by BOESEN, AGNIESZKA is 44 months. This places the examiner in the 14% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +35.7% benefit to allowance rate for applications examined by BOESEN, AGNIESZKA. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 71% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 75.0% of cases where such amendments are filed. This entry rate is in the 94% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 120.0% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.